Search for: [Abstract = "c DMARDs \(csDMARDs\). Drug survival was 83% after 1 year, 66% after 2 years, 53% after 3 years, 46% after 4 years and 34% after 5 years of follow\-up. No significant differences in drug survival between concomitant and non\-concomitant users of csDMARDs \(p = 0.47\), in patients naïve to and previously exposed to bDMARDs \(p = 0.25\) were observed. Significantly better drug survival was noted in patients with positive rheumatoid factor \(RF, p < 0.01\). RF\-seropositivity was also independently associated with a better drug survival in Cox regression analysis \(hazard ratio 0.561\). The most common reason for drug discontinuation was physician's decision \(36.2%\), followed by lack or loss of treatment efficacy \(19.2%\). Among 110 RA patients treated with biosimilar RTX, GP2013, 88 underwent mandatory non\-medical switch and 22 naive to RTX started treatment with GP2013. All analyzed disease activity indices were initially significantly higher in patients starting treatment from GP2013. In this subgroup, after 1 year of treatment, improvement in all disease activity scores and PROs was observed and maintained after 2 years of follow\-up. Changes were statistically significant for erythrocyte sedimentation rate \(ESR, p = 0.004\), number of swollen \(SJC28, p = 0.043\) and tender joint counts \(TJC28, p = 0.001\), DAS28\-ESR \(p = 0.014\), DAS28 calculated with c\-reactive protein \(DAS28\-CR"]
